Global Dilated Cardiomyopathy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Dilated Cardiomyopathy treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including Array BioPharma , Berlin Cures GmbH, Capricor Therapeutics Inc, Celixir Ltd, Hemostemix Inc and others.
A Significant contribution to the Dilated Cardiomyopathy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Dilated Cardiomyopathy pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Dilated Cardiomyopathy condition and increased access to investments is encouraging growth of Dilated Cardiomyopathy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Dilated Cardiomyopathy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Dilated Cardiomyopathy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Dilated Cardiomyopathy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Dilated Cardiomyopathy. Further, orphan drug status, fast track designation, grants awarded and other special status for Dilated Cardiomyopathy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Dilated Cardiomyopathy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Dilated Cardiomyopathy Pipeline candidates-
A Significant contribution to the Dilated Cardiomyopathy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Dilated Cardiomyopathy pipeline included 8 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Dilated Cardiomyopathy condition and increased access to investments is encouraging growth of Dilated Cardiomyopathy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Dilated Cardiomyopathy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Dilated Cardiomyopathy therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Dilated Cardiomyopathy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Dilated Cardiomyopathy. Further, orphan drug status, fast track designation, grants awarded and other special status for Dilated Cardiomyopathy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Dilated Cardiomyopathy pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Dilated Cardiomyopathy Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Dilated Cardiomyopathy drugs
- Late phase: Phase 3 and in-approval Dilated Cardiomyopathy drugs
- Company overview
- Snapshot
- Dilated Cardiomyopathy therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Dilated Cardiomyopathy- Disease Overview
2.2 Dilated Cardiomyopathy- Pipeline Snapshot
2.3 Dilated Cardiomyopathy- Pipeline Drugs by Phase
2.4 Dilated Cardiomyopathy- Pipeline Drugs by Company
2.5 Dilated Cardiomyopathy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Array BioPharma Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.2 Berlin Cures GmbH Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.3 Capricor Therapeutics Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.4 Celixir Ltd Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.5 Hemostemix Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.6 Martin Pharmaceuticals Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.7 MyoKardia In Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.8 Renovacor Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Dilated Cardiomyopathy- Phase 1 Drug Details
4.2 Dilated Cardiomyopathy- Phase 1 Drug Overview
4.3 Dilated Cardiomyopathy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Dilated Cardiomyopathy- Phase 2 Drug Details
5.2 Dilated Cardiomyopathy- Phase 2 Drug Overview
5.3 Dilated Cardiomyopathy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Dilated Cardiomyopathy- Phase 3 Drug Details
6.2 Dilated Cardiomyopathy- Phase 3 Drug Overview
6.3 Dilated Cardiomyopathy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Dilated Cardiomyopathy- Pre-clinical Phase Drug Details
7.2 Dilated Cardiomyopathy- Pre-clinical Phase Drug Overview
7.3 Dilated Cardiomyopathy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Dilated Cardiomyopathy- Disease Overview
2.2 Dilated Cardiomyopathy- Pipeline Snapshot
2.3 Dilated Cardiomyopathy- Pipeline Drugs by Phase
2.4 Dilated Cardiomyopathy- Pipeline Drugs by Company
2.5 Dilated Cardiomyopathy- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Array BioPharma Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.2 Berlin Cures GmbH Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.3 Capricor Therapeutics Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.4 Celixir Ltd Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.5 Hemostemix Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.6 Martin Pharmaceuticals Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.7 MyoKardia In Dilated Cardiomyopathy Drug Pipeline, H2- 2019
3.8 Renovacor Inc Dilated Cardiomyopathy Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Dilated Cardiomyopathy- Phase 1 Drug Details
4.2 Dilated Cardiomyopathy- Phase 1 Drug Overview
4.3 Dilated Cardiomyopathy- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Dilated Cardiomyopathy- Phase 2 Drug Details
5.2 Dilated Cardiomyopathy- Phase 2 Drug Overview
5.3 Dilated Cardiomyopathy- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Dilated Cardiomyopathy- Phase 3 Drug Details
6.2 Dilated Cardiomyopathy- Phase 3 Drug Overview
6.3 Dilated Cardiomyopathy- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Dilated Cardiomyopathy- Pre-clinical Phase Drug Details
7.2 Dilated Cardiomyopathy- Pre-clinical Phase Drug Overview
7.3 Dilated Cardiomyopathy- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
